FOSL1 and cancer: Targeted RNA sequencing, performed on FFPE‐derived cDNA using TruSight® RNA Pan‐Cancer Panel, confirmed the FOSL1 breakpoint at the transcript level (Figure 1B), which was further corroborated by strong nuclear immunoreactivity for FOSL1 (Figure 1C).